Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1001 to 1050 of 1326 results for nice quality standards or clinical guidelines

  1. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

  2. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    NG56/3 Question Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people...

  3. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  4. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment (HTG739)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.

  5. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

  6. Kidney conditions: CKD urine albumin:creatinine ratio (IND144)

    This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109

  7. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

  8. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

  9. Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.

  10. Irreversible electroporation for treating prostate cancer (HTG688)

    Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.

  11. Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee (HTG203)

    Evidence-based recommendations on individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee. This involves inserting an individually designed implant at the knee between the thigh and shin bones to realign the knee and prevent bone-on-bone rubbing.

  12. Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids (HTG590)

    Evidence-based recommendations on hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids in adults. This involves cutting the fibroids into small pieces to remove them.

  13. Stretta System for gastro-oesophageal reflux disease (MIB74)

    NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease

  14. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTG664)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.

  15. Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)

    Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.

  16. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (HTG549)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.

  17. Diabetes: annual albumin creatinine test (IND111)

    This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  18. Transabdominal artificial bowel sphincter implantation for faecal incontinence (HTG177)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

  19. Archimedes for biopsy of suspected lung cancer (MIB211)

    NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer .

  20. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.

  21. Key question: caring

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  22. ColonFlag for identifying people at risk of colorectal cancer (MIB142)

    NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

  23. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  24. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  25. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

  26. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  27. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

  28. Lung volume reduction surgery for advanced emphysema (HTG69)

    Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.

  29. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

  30. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.

  31. What is the clinical and cost effectiveness of psychological intervention alone, compared with antipsychotic medication and compared with psychological intervention and antipsychotic medication combined, in young people with first episode psychosis?

    Recommendation ID CG155/4 Question What is the clinical and cost effectiveness of psychological intervention alone, compared with...

  32. ATEC system for vacuum-assisted breast biopsy (MIB43)

    NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system

  33. The PediGuard for placing pedicle screws in spinal surgery (MIB26)

    NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery

  34. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG329)

    Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.

  35. Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

    Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.

  36. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

  37. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  38. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  39. Heart failure: 4 pillars (HFrEF) (IND317)

    This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  40. HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)

    NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .

  41. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  42. Diabetes: lipid-lowering therapies for secondary prevention of CVD (IND276)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  43. Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)

    NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns

  44. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

    Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.

  45. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

  46. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

  47. Hip fracture: surgery on the day or day after admission (IND14)

    This indicator covers the proportion of people with hip fracture, who receive surgery on the day of, or the day after, admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG21

  48. Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)

    NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis .

  49. Hypertension: confirming diagnosis with HBPM or ABPM (IND115)

    This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66